Immunohistochemichal expression of biomarkers: a comparative study between diagnostic bronchial biopsies and surgical specimens of non-small-cell lung cancer
Open Access
- 12 March 2007
- journal article
- research article
- Published by Elsevier in Annals of Oncology
- Vol. 18 (6) , 1043-1050
- https://doi.org/10.1093/annonc/mdm072
Abstract
Background: The increasing use of biomarkers as molecular determinants of responsiveness to conventional chemotherapy or molecular targeted therapy has raised the question of the reliability and reproducibility of their evaluation in bronchial biopsies as compared with corresponding resected surgical specimens. Patients and methods: Immunohistochemical expression of five markers related to signal transduction [epidermal growth factor receptor (EGFR), phospho-Akt], cell proliferation (Ki-67), DNA repair [excision repair cross-complementing (ERCC)1] and cellular ‘immortality’ [human telomerase catalytic component (hTERT)], was assessed in 41 patients with operable non-small-cell lung cancer in both bronchial biopsies and whole surgical specimens. Results: High correlation coefficients were observed between the expression of ERCC1, hTERT and Ki-67 in the biopsies and the surgical specimens [0.83 (P < 0.0001); 0.55 (P < 0.001) and 0.64 (P < 0.0001), respectively]. On the other hand, biomarker expression in biopsy was less correlated with the expression in the whole tissue sample for the markers of signal response and transduction [0.24 (P = 0.17) and 0.29 (P = 0.09) for EGFR and phospho-Akt, respectively]. Conclusions: Our results indicate a lack of association in the expression of important biomarkers between lung biopsies and corresponding resected tumors, with discordance rates ranging between 9% and 41%. Although these results need to be further validated in larger cohorts, they indicate that the evaluation of the expression of biomarkers in bronchial biopsies can be misleading.Keywords
This publication has 28 references indexed in Scilit:
- Cancer Statistics, 2006CA: A Cancer Journal for Clinicians, 2006
- Erlotinib in Lung Cancer — Molecular and Clinical Predictors of OutcomeNew England Journal of Medicine, 2005
- Phospho-Akt Overexpression in Non–Small Cell Lung Cancer Confers Significant Stage-Independent Survival DisadvantageClinical Cancer Research, 2004
- Akt Phosphorylation and Gefitinib Efficacy in Patients With Advanced Non-Small-Cell Lung CancerJNCI Journal of the National Cancer Institute, 2004
- The role of targeted therapy in non-small cell lung cancerCritical Reviews in Oncology/Hematology, 2004
- Frequent activation of AKT in non-small cell lung carcinomas and preneoplastic bronchial lesionsCarcinogenesis: Integrative Cancer Research, 2004
- The role of EGF-R expression on patient survival in lung cancer: a systematic review with meta-analysisEuropean Respiratory Journal, 2002
- Ligand-Induced, Receptor-Mediated Dimerization and Activation of EGF ReceptorPublished by Elsevier ,2002
- The phosphatidylinositol 3-Kinase–AKT pathway in human cancerNature Reviews Cancer, 2002
- Nucleotide excision repair II: from yeast to mammalsTrends in Genetics, 1993